EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Indications for venom immunotherapy






Monograph on insect allergy (Ed. 2): 53-56

Indications for venom immunotherapy

Indications for initiation of immunotherapy against the venoms of stinging Hymenoptera are discussed.


Accession: 001615619



Related references

Urbanek, R.; Kemeny, D.M.; Richards, D., 1986: Sub-class of IgG anti-bee venom antibody produced during bee venom immunotherapy and its relationship to long-term protection from bee stings and following termination of venom immunotherapy. The IgG sub-class antibody response to bee venom in the four sub-classes was investigated in ten patients during and after venom immunotherapy. All patients tolerated a bee sting challenge 1, 2 and 3 years after the start of treatment as well as 1...

Urbanek, R.; Kemeny, D.M.; Richards, D., 1986: Sub-class of IgG anti-bee venom antibody produced during bee venom immunotherapy and its relationship to long-term protection from bee stings and following termination of venom immunotherapy. The IgG sub-class antibody response to bee venom in the four sub-classes was investigated in ten patients during and after venom immunotherapy. All patients tolerated a bee sting challenge 1, 2 and 3 years after the start of treatment as well as 1...

Urbanek R.; Kemeny D.M.; Richards D., 1986: Subclass of immunoglobulin g anti bee venom antibody produced during bee venom immunotherapy and its relationship to long term protection from bee stings and following termination of venom immunotherapy. The IgG sub-class antibody response to bee venom in the four sub-classes was investigated in ten patients during and after venom immunotherapy. All patients tolerated a bee sting challenge 1,2 and 3 years after the start of treatment as well as 1...

Reisman, R.E., 1986: Indications for discontinuation of venom immunotherapy. Indications for the discontinuation of immunotherapy against the venoms of stinging Hymenoptera are discussed in terms of observations related to the natural history of stinging insect allergy and decreases in venom-specific IgE to insignificant l...

Birnbaum, J.; Vervloet, D., 2004: Venom allergy: indications for immunotherapy according to recent epidemiological data. In most cases, hymenoptera venom allergy is caused by bees or wasps, but also occasionally by hornets, bumblebees or other members of the Vespidae family. The prevalence of sensitization to venom in adults who have not had an allergic reaction fol...

Lesourd, B.; Paupe, J.; Thiollet, M.; Moulias, R.; Sainte Laudy, J.; Scheinmann, P., 1989: Hymenoptera venom immunotherapy. I. Induction of T cell-mediated immunity by honeybee venom immunotherapy: relationships with specific antibody responses. The specific cell-mediated and humoral immune responses of 14 children allergic to honeybee venom were studied. An 8-day rush venom immunotherapy induced an increase in T proliferative (p less than 0.04) and T suppressive (p less than 0.003) cell-...

Lesourd, B.; Paupe, J.; Thiollet, M.; Moulias, R.; Sainte-Laudy, J.; Scheinmann, P., 1989: Hymenoptera venom immunotherapy. I. Induction of T cell-mediated immunity by honeybee venom immunotherapy: relationships with specific antibody responses. The specific cell-mediated and humoral immune responses of 14 children allergic to honeybee venom were studied. An 8-day rush venom immunotherapy induced an increase in T proliferative (p less than 0.04) and T suppressive (p less than 0.003) cell-...

Goldberg, A.; Confino-Cohen, R., 2003: Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. An unknown number of venom-allergic patients fail to reach the maintenance dose (MD) during the build-up period of conventional venom immunotherapy (VIT) due to recurrent systemic reactions (SRs). To establish an alternative VIT protocol that will...

Fischer, D.A.; Payton, K.B.; Butchey, J.R.K., 1996: Rush venom immunotherapy in patient with previous anaphylaxis during venom immunotherapy. Journal of Allergy & Clinical Immunology 97(1 PART 3): 338

Muller, U.; Fricker, M.; Akdis, A.C.; Carballido, J.; Blaser, K., 1996: Successful immunotherapy with T-cell epitopes of bee venom phospholipase A-2 in patients with bee venom allergy. Journal of Allergy & Clinical Immunology 97(1 PART 3): 426